{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T04:21:40Z","timestamp":1744258900100,"version":"3.40.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"AryoGen Pharmed Company"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s00277-025-06242-z","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T01:28:18Z","timestamp":1739323698000},"page":"1195-1202","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A randomized, two-armed, double-blind, single-dose, cross-over, bioequivalence clinical trial to compare pharmacokinetic parameters and safety of recombinant human factor VIII with Fc fusion produced by AryoGen Pharmed Company versus Elocta\u00ae (reference product) in previously treated patients with severe haemophilia A"],"prefix":"10.1007","volume":"104","author":[{"given":"Aziz","family":"Eghbali","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peyman","family":"Eshghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gholamreza","family":"Toogeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samin","family":"Alavi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahra","family":"Badiei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Majid","family":"Ghanavat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammadreza","family":"Bordbar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asghar","family":"Bazrafshan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katayoon","family":"Karimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minoo","family":"Ahmadinejad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Araz","family":"Sabzvari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1246-8969","authenticated-orcid":false,"given":"Hamidreza","family":"Kafi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,12]]},"reference":[{"key":"6242_CR1","unstructured":"Keith Hoots W MDS, MD (2021) Hemophilia A and B: routine management including prophylaxis. In: TW P (ed) UpToDate. Wolters Kluwer"},{"key":"6242_CR2","unstructured":"WFH guidelines for the management of hemophilia (2020)"},{"key":"6242_CR3","unstructured":"Report On The Annual Global Survey (2020) [Available from: https:\/\/www1.wfh.org\/publications\/files\/pdf-2045.pdf]"},{"key":"6242_CR4","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.bcmd.2017.02.004","volume":"67","author":"K Fischer","year":"2017","unstructured":"Fischer K, Ljung R (2017) Primary prophylaxis in haemophilia care: Guideline update 2016. Blood Cells Molecules Dis 67:81\u201385","journal-title":"Blood Cells Molecules Dis"},{"issue":"3","key":"6242_CR5","first-page":"e12202","volume":"3","author":"K Usuba","year":"2019","unstructured":"Usuba K, Price VE, Blanchette V, Abad A, Altisent C, Buchner-Daley L, Carneiro JD, Feldman BM, Fischer K, Grainger J (2019) Impact of prophylaxis on health\u2010related quality of life of boys with hemophilia: an analysis of pooled data from 9 countries. Res Pract Thromb Haemostasis 3(3):e12202","journal-title":"Res Pract Thromb Haemostasis"},{"key":"6242_CR6","doi-asserted-by":"crossref","unstructured":"Thornburg CD, Duncan NA (2017) Treatment adherence in hemophilia. Patient Prefer Adherence:1677\u20131686","DOI":"10.2147\/PPA.S139851"},{"issue":"2","key":"6242_CR7","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1159\/000488060","volume":"45","author":"L Graf","year":"2018","unstructured":"Graf L (2018) Extended half-life factor VIII and factor IX preparations. Transfus Med Hemotherapy 45(2):86\u201391","journal-title":"Transfus Med Hemotherapy"},{"issue":"2","key":"6242_CR8","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3109\/07388551.2013.834293","volume":"35","author":"T Rath","year":"2015","unstructured":"Rath T, Baker K, Dumont JA, Peters RT, Jiang H, Qiao S-W, Lencer WI, Pierce GF, Blumberg RS (2015) Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics. Crit Rev Biotechnol 35(2):235\u2013254","journal-title":"Crit Rev Biotechnol"},{"key":"6242_CR9","first-page":"365","volume-title":"Fc-fusion technology and recombinant FVIII and FIX in the management of the hemophilias","author":"ME Mancuso","year":"2014","unstructured":"Mancuso ME, Mannucci PM (2014) Fc-fusion technology and recombinant FVIII and FIX in the management of the hemophilias. Drug Design, Development and Therapy, pp 365\u2013371"},{"key":"6242_CR10","unstructured":"FDA Clears First Long-Acting Hemophilia A Drug (Eloctate) - Medscape - Jun 09, 2014. https:\/\/www.medscape.com\/viewarticle\/826438?form=fpf"},{"issue":"3","key":"6242_CR11","first-page":"317","volume":"123","author":"J Mahlangu","year":"2014","unstructured":"Mahlangu J, Powell JS, Ragni MV, Chowdary P, Josephson NC, Pabinger I, Hanabusa H, Gupta N, Kulkarni R, Fogarty P (2014) Phase 3 study of recombinant factor VIII fc fusion protein in severe hemophilia A. Blood. J Am Soc Hematol 123(3):317\u2013325","journal-title":"J Am Soc Hematol"},{"issue":"13","key":"6242_CR12","first-page":"3031","volume":"119","author":"JS Powell","year":"2012","unstructured":"Powell JS, Josephson NC, Quon D, Ragni MV, Cheng G, Li E, Jiang H, Li L, Dumont JA, Goyal J (2012) Safety and prolonged activity of recombinant factor VIII fc fusion protein in hemophilia A patients. Blood J Am Soc Hematol 119(13):3031\u20133037","journal-title":"Blood J Am Soc Hematol"},{"issue":"6","key":"6242_CR13","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/jth.12911","volume":"13","author":"G Young","year":"2015","unstructured":"Young G, Mahlangu J, Kulkarni R, Nolan B, Liesner R, Pasi J, Barnes C, Neelakantan S, Gambino G, Cristiano L (2015) Recombinant factor VIII fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A. J Thromb Haemost 13(6):967\u2013977","journal-title":"J Thromb Haemost"},{"issue":"1","key":"6242_CR14","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/hae.12766","volume":"22","author":"B Nolan","year":"2016","unstructured":"Nolan B, Mahlangu J, Perry D, Young G, Liesner R, Konkle B, Rangarajan S, Brown S, Hanabusa H, Pasi K (2016) Long-term safety and efficacy of recombinant factor VIII fc fusion protein (rFVIIIFc) in subjects with haemophilia A. Haemophilia 22(1):72\u201380","journal-title":"Haemophilia"},{"issue":"3","key":"6242_CR15","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/hae.13953","volume":"26","author":"B Nolan","year":"2020","unstructured":"Nolan B, Mahlangu J, Pabinger I, Young G, Konkle BA, Barnes C, Nogami K, Santagostino E, Pasi KJ, Khoo L (2020) Recombinant factor VIII fc fusion protein for the treatment of severe haemophilia A: final results from the ASPIRE extension study. Haemophilia 26(3):494\u2013502","journal-title":"Haemophilia"},{"issue":"6","key":"6242_CR16","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1111\/hae.13834","volume":"25","author":"F Peyvandi","year":"2019","unstructured":"Peyvandi F, Garagiola I, Boscarino M, Ryan A, Hermans C, Makris M (2019) Real-life experience in switching to new extended half\u2010life products at European haemophilia centres. Haemophilia 25(6):946\u2013952","journal-title":"Haemophilia"},{"key":"6242_CR17","unstructured":"Scott M, Xiang H, Collins PW, Hay CR The effect of switching to rFVIIIFc on treatment patterns and annualised bleed rate before and after: a within-patient comparison from the UK National Haemophilia Database. In: Haemophilia, 2018. Wiley 111 RIVER ST, HOBOKEN 07030\u2013\u20095774, NJ USA, pp 91\u201392"},{"key":"6242_CR18","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.thromres.2018.08.004","volume":"170","author":"A McEneny-King","year":"2018","unstructured":"McEneny-King A, Chelle P, Iorio A, Edginton A (2018) The effect of unmeasurable endogenous plasma factor activity levels on factor VIII dosing in patients with severe hemophilia A. Thromb Res 170:53\u201359","journal-title":"Thromb Res"},{"issue":"4","key":"6242_CR19","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/hae.13013","volume":"22","author":"P Collins","year":"2016","unstructured":"Collins P, Chalmers E, Chowdary P, Keeling D, Mathias M, O\u2019donnell J, Pasi K, Rangarajan S, Thomas A (2016) The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO. Haemophilia 22(4):487\u2013498","journal-title":"Haemophilia"},{"key":"6242_CR20","unstructured":"Common Terminology (2017) Criteria for Adverse Events (CTCAE) Version 5.0"},{"key":"6242_CR21","unstructured":"Maintenance of the ICH Guideline on Clinical Safety Data MANAGEMENT: Data Elements for Transmission of Individual Case Safety Reports E2B(R2) (2001)"},{"issue":"3","key":"6242_CR22","doi-asserted-by":"crossref","first-page":"325","DOI":"10.4103\/0019-5049.115608","volume":"57","author":"S Parida","year":"2013","unstructured":"Parida S (2013) Clinical causality assessment for adverse drug reactions. Indian J Anaesth 57(3):325\u2013326","journal-title":"Indian J Anaesth"},{"issue":"8","key":"6242_CR23","doi-asserted-by":"crossref","first-page":"5287","DOI":"10.1074\/jbc.M607816200","volume":"282","author":"K Nogami","year":"2007","unstructured":"Nogami K, Shima M, Matsumoto T, Nishiya K, Tanaka I, Yoshioka A (2007) Mechanisms of plasmin-catalyzed inactivation of factor VIII: a crucial role for proteolytic cleavage at Arg336 responsible for plasmin-catalyzed factor VIII inactivation. J Biol Chem 282(8):5287\u20135295","journal-title":"J Biol Chem"},{"issue":"Supplement 1","key":"6242_CR24","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1182\/blood-2018-99-110036","volume":"132","author":"C Pouplard","year":"2018","unstructured":"Pouplard C, Sattler L, Ryman A, Eschwege V, De Maistre E, Flaujac C, Szymezak J, Grand F, Repesse Y, Galinat H, Donnard M, Ternisien C, Jeanpierre E (2018) Multicenter Pharmacokinetic evaluation of rFVIII-Fc (Elocta) in a real life and comparison with non-extended half-life FVIII concentrates. Blood 132(Supplement 1):1196\u20131196. https:\/\/doi.org\/10.1182\/blood-2018-99-110036","journal-title":"Blood"},{"issue":"6","key":"6242_CR25","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2491\/jjsth.27.665","volume":"27","author":"H HANABUSA","year":"2016","unstructured":"Hanabusa H, Shima M, nogami K, Matsushita T, Fukutake K, Taki M, Sakai M, Dong Y, Neelakantan S, Cristiano LM (2016) Evaluation of the safety, pharmacokinetics, and efficacy of recombinant factor VIII fc fusion protein in Japanese subjects with severe haemophilia A: analysis from the A-LONG study. Japanese J Thromb Hemost 27(6):665\u2013677","journal-title":"Japanese J Thromb Hemost"},{"issue":"4","key":"6242_CR26","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/hae.14078","volume":"26","author":"PL Turecek","year":"2020","unstructured":"Turecek PL, Johnsen JM, Pipe SW, O\u2019Donnell JS, Group iS (2020) Biological mechanisms underlying inter-individual variation in factor VIII clearance in haemophilia. Haemophilia 26(4):575\u2013583","journal-title":"Haemophilia"},{"key":"6242_CR27","doi-asserted-by":"crossref","unstructured":"Kim SK, Yoo KY, Lee KS, Hwang T, Choi YM, Choi EJ, Park SK (2018) Safety and efficacy of B-domain deleted third generation recombinant factor VIII (GreenGene F\u2122) in Korean patients with hemophilia A: data from a post-marketing surveillance study. J Korean Med Sci 33 (1)","DOI":"10.3346\/jkms.2018.33.e5"},{"issue":"4","key":"6242_CR28","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1111\/hae.14797","volume":"29","author":"J Blatn\u00fd","year":"2023","unstructured":"Blatn\u00fd J, Nielsen EM, Reitzel SB, McMillan AC, Dan\u00f8 A, Bystrick\u00e1 L, Kragh N, Klamroth R (2023) Real-world evidence on efmoroctocog alfa in patients with haemophilia A: a systematic literature review of treatment experience in Europe. Haemophilia 29(4):963\u2013974. https:\/\/doi.org\/10.1111\/hae.14797","journal-title":"Haemophilia"},{"issue":"6","key":"6242_CR29","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1111\/hae.14123","volume":"26","author":"SL Meeks","year":"2020","unstructured":"Meeks SL, Lacroix-Desmazes S (2020) Emerging benefits of fc fusion technology in the context of recombinant factor VIII replacement therapy. Haemophilia 26(6):958\u2013965. https:\/\/doi.org\/10.1111\/hae.14123","journal-title":"Haemophilia"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06242-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06242-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06242-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T16:52:09Z","timestamp":1744217529000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06242-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["6242"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06242-z","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"23 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approvals for this study has been achieved from Research Ethics Committee of Iran University of Medical Sciences by the following case number: IR.IUMS.REC.1402.03.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The study was performed in accordance with Good Clinical Practice (GCP) guidelines and the Declaration of Helsinki. Each participant signed a written informed consent form before the initiation of the trial.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}},{"value":"This clinical trial has been registered in ClinicalTrials.gov (NCT06137092).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial registration"}},{"value":"Aziz Eghbali received educational\/research grants and travel supports to attend scientific meetings from Cinnagen (in addition to lecture honorarium), Baxter, and CSL. Peyman Eshghi has received: educational\/research grants from Cinnagen (in addition to lecture honorarium), Biotest, Baxter, Novonordisk, and Pfizer. Moreover, he received travel supports to attend scientific meetings from all of the above and CSL. Samin Alavi has received research grant from Cinnagen and travel support from Baxter to attend a scientific meeting. Zahra Badiei has received educational\/research grants and lecture honorarium from Cinnagen. Moreover, she received travel supports to attend scientific meetings from Baxter, Novo Nordisk, CSL, and Cinnagen. Mohammadreza Bordbar has received lecture honorarium and travel support to attend scientific programs from Novartis and Aryogen Pharmed Company. Hamidreza Kafi is head of the Medical Department of Orchid Pharmed Company, which is in collaboration with AryoGen Pharmed Company with respect to conducting clinical trials. Moreover, Araz Sabzvari is a member of the CinnaGen Medical Biotechnology Research Center, which collaborates with universities and researchers all over the world with regards to research and development of medications and health issues. Other contributors declared no related conflict of interest to this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}